These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34633688)

  • 1. Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation.
    Roche L; Moriarty B; Fabre A; Crowne J; Lally A
    Clin Exp Dermatol; 2022 Mar; 47(3):582-584. PubMed ID: 34633688
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 3. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 4. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 5. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 6. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 7. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
    Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
    J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 9. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
    Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
    [No Abstract]   [Full Text] [Related]  

  • 10. Common skin cancers.
    Lee PK
    Minn Med; 2004 Mar; 87(3):44-7. PubMed ID: 15080294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
    Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
    Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 13. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
    Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
    J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
    [No Abstract]   [Full Text] [Related]  

  • 14. Pembrolizumab for Recurrent Conjunctival Melanoma.
    Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
    JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
    Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
    JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
    Jang S; Venna S
    J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
    [No Abstract]   [Full Text] [Related]  

  • 17. Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients.
    Handa T; Kato J; Sumikawa Y; Hida T; Horimoto K; Sato S; Sawada M; Fujioka M; Minowa T; Matsui Y; Uhara H
    J Dermatol; 2019 Dec; 46(12):e461-e462. PubMed ID: 31583754
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
    Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract]   [Full Text] [Related]  

  • 20. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.